浙江永強(002489.SZ):實控人之一謝建平質押7000萬股及解押2800萬股
格隆匯12月3日丨浙江永強(002489.SZ)公佈,公司近日接到實際控制人之一謝建平通知,獲悉謝建平因個人資金需求已將其所持7000萬股質押給國泰君安,佔其所持股份的54.53%;及謝建平已將其持有並質押給國泰君安的2800萬股辦理解除質押,佔其所持股份的21.81%。
截至公告日,謝建平持有公司股份1.2837億股,佔公司總股本的5.90%;累計質押公司股份7000萬股,佔其所持股份的54.53%,佔公司總股本的3.22%。
截至公告日,公司控股股東及實際控制人合計持有公司股份12.1780億股,累計質押公司股份5.5233億股,佔其合計所持股份的45.35%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.